Hiroyuki Kouji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroyuki Kouji has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Takenao Odagami
Research Institute, Midori-ku, Yokohama, Japan
2 shared publications- Yoshio Okada
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA
2 shared publications Yuji Kogami
Research Institute, PRISM Bio Lab
2 shared publications- Yuko Tsuda
Department of Pediatrics, Wakayama Medical University, Wakayama City, Wakayama, Japan
2 shared publications Akira Katoh
Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Yufu, Oita, 879-5593, Japan
1 shared publication- Akira Katoh
Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine Oita University Yufu Oita Japan
1 shared publication
Latest Publications
- Open Access
- 1 January 2019
- Published by XMLink in Annals of Dermatology
- Vol. 31 (6) , 631-639
Selective Inhibition of β-Catenin/Co-Activator Cyclic AMP Response Element-Binding Protein-Dependent Signaling Prevents the Emergence of Hapten-Induced Atopic Dermatitis-Like Dermatitis
The canonical Wnt/β-catenin signaling pathway is a fundamental regulatory system involved in various biological events. ICG-001 selectively blocks the interaction of β-catenin with its transcriptional co-activator cyclic AMP response element-binding protein (CBP). Recent studies have provided convincing evidence of the inhibitory effects of ICG-001 on Wnt-driven disease models, such as organ fibrosis, cancer, acute lymphoblastic leukemia, and asthma. However, the effects of ICG-001 in atopic dermatitis (AD) have not been investigated. To investigate whether β-catenin/CBP-dependent signaling was contributed in the pathogenesis of AD and ICG-001 could be a therapeutic agent for AD. We examined the effects of ICG-001 in an AD-like murine model generated by repeated topical application of the hapten, oxazolone (Ox). ICG-001 or vehicle alone was injected intraperitoneally every day during the development of AD-like dermatitis arising from once-daily Ox treatment. Ox-induced AD-like dermatitis characterized by increases in transepidermal water loss, epidermal thickness, dermal thickness accompanied by increased myofibroblast and mast cell counts, and serum levels of thymic stromal lymphopoietin and thymus and activation-regulated chemokine, and decreases in stratum corneum hydration, were virtually normalized by the treatment with ICG-001. Elevated serum levels of periostin tended to be downregulated, without statistical significance. These results suggest that β-catenin/CBP-dependent signaling might be involved in the pathogenesis of AD and could be a therapeutic target.
- 1 January 2019
- Published by XMLink in Annals of Dermatology
- Vol. 31 (6) , 631-639
Open AccessSelective Inhibition of β-Catenin/Co-Activator Cyclic AMP Response Element-Binding Protein-Dependent Signaling Prevents the Emergence of Hapten-Induced Atopic Dermatitis-Like Dermatitis
The canonical Wnt/β-catenin signaling pathway is a fundamental regulatory system involved in various biological events. ICG-001 selectively blocks the interaction of β-catenin with its transcriptional co-activator cyclic AMP response element-binding protein (CBP). Recent studies have provided convincing evidence of the inhibitory effects of ICG-001 on Wnt-driven disease models, such as organ fibrosis, cancer, acute lymphoblastic leukemia, and asthma. However, the effects of ICG-001 in atopic dermatitis (AD) have not been investigated. To investigate whether β-catenin/CBP-dependent signaling was contributed in the pathogenesis of AD and ICG-001 could be a therapeutic agent for AD. We examined the effects of ICG-001 in an AD-like murine model generated by repeated topical application of the hapten, oxazolone (Ox). ICG-001 or vehicle alone was injected intraperitoneally every day during the development of AD-like dermatitis arising from once-daily Ox treatment. Ox-induced AD-like dermatitis characterized by increases in transepidermal water loss, epidermal thickness, dermal thickness accompanied by increased myofibroblast and mast cell counts, and serum levels of thymic stromal lymphopoietin and thymus and activation-regulated chemokine, and decreases in stratum corneum hydration, were virtually normalized by the treatment with ICG-001. Elevated serum levels of periostin tended to be downregulated, without statistical significance. These results suggest that β-catenin/CBP-dependent signaling might be involved in the pathogenesis of AD and could be a therapeutic target.
- Open Access
- 1 January 2009
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 57 (2) , 211-213
Deprotection of the Indole (Nind)-Formyl (For) Group on Tryptophan Employing a New Reagent, N,N'-Dimethylethylendiamine (DMEDA) in an Aqueous Solution
The deprotection of the indole (Nind)-formyl (For) group on Trp was achieved in a 95% yield using N,N′-dimethylethylendiamine (DMEDA) (1.5, 2.0, 3.0 eq) in water at room temperature. A new reagent was successfully applied to the deprotection of a model peptide, H-Phe-Trp(Nind-For)-Lys-Tyr-OH, to give H-Phe-Trp-Lys-Tyr-OH in a 91% yield.
- 1 January 2009
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 57 (2) , 211-213
Open AccessDeprotection of the Indole (Nind)-Formyl (For) Group on Tryptophan Employing a New Reagent, N,N'-Dimethylethylendiamine (DMEDA) in an Aqueous Solution
The deprotection of the indole (Nind)-formyl (For) group on Trp was achieved in a 95% yield using N,N′-dimethylethylendiamine (DMEDA) (1.5, 2.0, 3.0 eq) in water at room temperature. A new reagent was successfully applied to the deprotection of a model peptide, H-Phe-Trp(Nind-For)-Lys-Tyr-OH, to give H-Phe-Trp-Lys-Tyr-OH in a 91% yield.
- 1 July 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (14) , 3723-3726
Design of cyclic peptides with agonist activity at melanocortin receptor-4
- 1 July 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (14) , 3723-3726
Design of cyclic peptides with agonist activity at melanocortin receptor-4